The Food and Drug Administration (FDA) has approved updates to Susvimo, an eye implant treatment for wet age-related macular degeneration (AMD). Susvimo provides an alternative to regular eye injections, the current standard of care.

Wet AMD affects approximately 1.5 million Americans and 20 million people worldwide. If left untreated, it can lead to blindness. Susvimo is the first and only approved treatment for wet AMD that maintains vision with just two refills per year.

Developed by Genentech, Susvimo is a refillable implant that continuously delivers a customized formulation of ranibizumab to the eye. The implant is surgically inserted during a one-time outpatient procedure and is refilled every six months.

The FDA approves the updated Susvimo based on component-level updates to the implant and refill needle. Genentech has conducted extensive testing to ensure that the implant and needle now meet performance standards.

Susvimo offers several advantages over traditional eye injections. It provides sustained delivery of medicine to the eye, reducing the need for frequent injections. Additionally, inserting and refilling the implant is less invasive than multiple eye injections.

Genentech is committed to helping patients access Susvimo. The company offers comprehensive services to minimize barriers to access and reimbursement. Patients can call 833-EYE-GENE for more information and to learn about patient assistance programs through Genentech Access Solutions.

Source link: http://www.businesswire.com/news/home/20240703748120/en/Genentech-to-Reintroduce-Susvimo-for-People-With-Wet-Age-related-Macular-Degeneration-AMD

Jon Napitupulu
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.